Cabaletta Bio (CABA) Stock Analysis & Winston Score

Cabaletta Bio is a clinical-stage biotechnology company working on treatments for serious autoimmune diseases. These are conditions where the body's immune system mistakenly attacks itself, causing damage to organs and tissues. The company's main focus is on using engineered immune cells, called CAR-T cells, to target and eliminate the specific cells responsible for driving diseases like lupus and myasthenia gravis.

Cabaletta does not yet sell any products, so it earns no revenue today. It funds its research through cash raised from investors and, at times, partnerships with larger pharmaceutical companies. The company operates primarily in the United States and is considered small, with a market cap around $600 million. Its main competitive edge is its focus on a specific type of immune cell targeting, but the biggest risk is that its experimental treatments could fail in clinical trials, which would significantly threaten the company's future.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+46.6% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

12.4%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~8 months

$117M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Cabaletta Bio has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-35.0%

Weak — -35.0% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.22

Conservative — low debt load (0.22)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial